Pfizer's Camptosar To Serve As Example Of Pharmacogenetic Toxicity Risk At Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Irinotecan will be used as an example of pharmacogenetic toxicity risk at Clinical Pharmacology Subcommittee meeting Nov. 3-4. Pfizer is discussing label changes with FDA regarding Camptosar use in patients with certain genotypes. Subcommittee will also address the transition of biomarkers to surrogate endpoints.
You may also be interested in...
Camptosar Genetic Test Launched By Genzyme
Invader assay identifies deficient UGT1A1*28 allele, which increases risk of neutropenia in colorectal cancer patients taking Camptosar.
Camptosar Genetic Test Launched By Genzyme
Invader assay identifies deficient UGT1A1*28 allele, which increases risk of neutropenia in colorectal cancer patients taking Camptosar.
Pharmacogenetic Data Integration Into Labeling To Be Discussed By Subcommittee
Clinical Pharmacology Subcommittee will meet Nov. 14-15 on several topics including pharmacogenetic data integration and the biomarker-surrogate endpoint project of FDA's "Critical Path" initiative.